Sorafekast 200mg Tablet

Sorafekast 200mg Tablet is an anticancer medicine with Sorafenib as an active ingredient. This tablet belongs to a group of medications called tyrosine kinase inhibitors. It is prescribed to treat certain types of cancer, including liver cancer, kidney cancer, and thyroid cancer. Sorafenib is a kinase inhibitor that helps to stop the growth of cancerous cells by blocking the action of an abnormal protein. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

• Thyroid cancer
• Kidney cancer
• Liver cancer

Like any other anticancer medicine, Sorafekast 200mg Tablet also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:

• Nausea
• Fatigue
• Loss of appetite
• Diarrhea
• Abdominal pain
• Hair loss
• Weight loss
• Rash
• Painful blisters on hands and feet

Seek medical attention in case of any unusual or severe side effects immediately.

• The dosage and duration of the Sorafekast 200mg Tablet are decided by the doctor based on the stage & type of cancer and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
• If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.
  
  

Sorafekast 200mg Tablet is an anticancer medicine. This tablet belongs to a group of medications called tyrosine kinase inhibitors works by blocking the action of the abnormal protein that is responsible for the uncontrolled growth of cancerous cells. It effectively slows down the progression of cancer by controlling the multiplication of cancer cells.

• Zhu, Y. J., Zheng, B., Wang, H. Y., & Chen, L. (2017). New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacologica Sinica, 38(5), 614-622.https://pubmed.ncbi.nlm.nih.gov/28344323/
• Woo, H. Y., & Heo, J. (2012). Sorafenib in liver cancer. Expert opinion on pharmacotherapy, 13(7), 1059-1067.https://pubmed.ncbi.nlm.nih.gov/22519770/
• Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., ... & Pazdur, R. (2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clinical cancer research, 12(24), 7271-7278. https://pubmed.ncbi.nlm.nih.gov/17189398/
• Zhu, Y. J., Zheng, B., Wang, H. Y., & Chen, L. (2017). New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacologica Sinica, 38(5), 614-622. https://pubmed.ncbi.nlm.nih.gov/28344323/
• Thomas, L., Lai, S. Y., Dong, W., Feng, L., Dadu, R., Regone, R. M., & Cabanillas, M. E. (2014). Sorafenib in metastatic thyroid cancer: a systematic review. The oncologist, 19(3), 251-258. https://pubmed.ncbi.nlm.nih.gov/24563075/
• Fallahi, P., Ferrari, S. M., Santini, F., Corrado, A., Materazzi, G., Ulisse, S., ... & Antonelli, A. (2013). Sorafenib and thyroid cancer. BioDrugs, 27(6), 615-628. https://pubmed.ncbi.nlm.nih.gov/23818056/